By Stephanie Brown HealthDay ReporterFRIDAY, May 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...

GSK Plc won US approval for its drug to treat a deadly lung disease, ramping up competition with rival Sanofi.

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as ...

Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil counts as low as ≥150 cells/μL.

FDA approves Nucala as add-on therapy for COPD with high eosinophils, offering new hope by reducing flare-ups in patients ...

University of Alabama at Birmingham-led researchers have refined and validated a new framework for diagnosing chronic ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...

Women with COPD, asthma, and OSA may go undiagnosed or without proper care because their symptomatology differs from the male ...